EUVIMEDEUVIMED entdecken
BeobachtungsstudieValidierungsstudie

Prospective validation study of nutritional and immunological predictors in immune checkpoint inhibitor efficacy for non‐small cell lung cancer

Shinkichi Takamori iD, Mototsugu Shimokawa, Masafumi Yamaguchi, Masahide Mori, Shoichi Kuyama, Masahide Oki, Yoshifumi Nishimura, Katsumi Nakatomi, Hidetoshi Yanai, Noriaki Sukoh, Nobuo Hatakeyama, Toshiyuki Kita und 4 weitere

International Journal of Cancer · 2026

DOI: 10.1002/ijc.70170 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift International Journal of Cancer, 2026. Verfasst von Shinkichi Takamori und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Oncology, NHO Kyushu Cancer Center, Fukuoka, Japan. Hauptthemen laut MEDLINE: Immune Checkpoint Inhibitors, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Nutritional Status. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 42 Literaturangaben. Gefördert von: Japanese Foundation for Multidisciplinary Treatment of Cancer, Foundation for Promotion of Cancer Research, Fukuoka Public Health Promotion Organization Cancer Research Fund.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Immune checkpoint inhibitors (ICIs) have improved prognosis in non‐small cell lung cancer (NSCLC). This prospective observational study aimed to validate the clinical impact of nutritional and immunological indices, including neutrophil‐to‐lymphocyte ratio (NLR), Glasgow prognostic score (GPS), prognostic nutritional index (PNI), controlling nutritional status (CONUT), and skeletal muscle area (SMA) in NSCLC patients treated with first‐line ICIs. Three hundred and one patients with programmed cell death‐ligand 1 (PD‐L1) expression data were enrolled. SMA was measured using computed tomography images at the L3 level. Cut‐off values were determined by our previous retrospective reports. The primary endpoint was progression‐free survival (PFS). As a translational research, 15 myokines were evaluated from pre‐treatment blood samples. The NLR, GPS, PNI, CONUT, and SMA were all significantly associated with PFS ( p = .0128, p = .0016, p = .0046, p = .0485, and p = .0161, respectively). Multivariate analysis elucidated that age ≥75 years ( p = .0256), male sex ( p = .0227), combined chemotherapy ( p = .0002), PD‐L1 ≥50% ( p = .0017), and SMA ( p = .0354) were significant predictors of objective response. Multivariate analysis of PFS showed that performance status ( p = .0104), PD‐L1 ( p

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immune Checkpoint InhibitorsCarcinoma, Non-Small-Cell LungLung NeoplasmsNutritional StatusHumansMaleFemaleAgedMiddle AgedProspective StudiesPrognosisNeutrophilsB7-H1 AntigenAged, 80 and overAdultNutrition AssessmentProgression-Free SurvivalMuscle, Skeletal

Stichwörter der Autor:innen

immune checkpoint inhibitormyokinenon‐small cell lung cancernutritionsarcopenia

Substanzen

Immune Checkpoint InhibitorsB7-H1 AntigenCD274 protein, human

Autor:innen und Institutionen

  • Department of Thoracic Oncology, NHO Kyushu Cancer Center, Fukuoka, Japan.
  • Department of Surgery and Science, Kyushu University, Fukuoka, Japan.
  • Department of Biostatistics, Yamaguchi University Graduate School of Medicine, Yamaguchi, Japan.
  • Department of Thoracic Oncology, NHO Osaka Toneyama Medical Center, Toyonaka, Japan.
  • Department of Respiratory Medicine, NHO Iwakuni Clinical Center, Iwakuni, Japan.
  • Department of Respiratory Medicine, NHO Nagoya Medical Center, Nagoya, Japan.

ORCID-Profile: Shinkichi Takamori

Förderung

  • Japanese Foundation for Multidisciplinary Treatment of Cancer
  • Foundation for Promotion of Cancer Research
  • Fukuoka Public Health Promotion Organization Cancer Research Fund
  • Grant of The Clinical Research Promotion Foundation (2022)
  • Kaibara Morikazu Medical Science Promotion Foundation
  • Japan Society for the Promotion of Science

Zitieren

APA

Takamori, S., Shimokawa, M., Yamaguchi, M., Mori, M., Kuyama, S., Oki, M., Nishimura, Y., Nakatomi, K., Yanai, H., Sukoh, N., Hatakeyama, N., Kita, T., Fujiwara, K., Chibana, K., Okamoto, M., & Takenoyama, M. (2026). Prospective validation study of nutritional and immunological predictors in immune checkpoint inhibitor efficacy for non‐small cell lung cancer. International Journal of Cancer. https://doi.org/10.1002/ijc.70170

Vancouver

Takamori S, Shimokawa M, Yamaguchi M, Mori M, Kuyama S, Oki M, et al. Prospective validation study of nutritional and immunological predictors in immune checkpoint inhibitor efficacy for non‐small cell lung cancer. International Journal of Cancer. 2026. doi:10.1002/ijc.70170

BibTeX
@article{Takamori2026,
  author = {Takamori, Shinkichi and Shimokawa, Mototsugu and Yamaguchi, Masafumi and Mori, Masahide and Kuyama, Shoichi and Oki, Masahide and Nishimura, Yoshifumi and Nakatomi, Katsumi and Yanai, Hidetoshi and Sukoh, Noriaki and Hatakeyama, Nobuo and Kita, Toshiyuki and Fujiwara, Keiichi and Chibana, Kenji and Okamoto, Masaki and Takenoyama, Mitsuhiro},
  title = {Prospective validation study of nutritional and immunological predictors in immune checkpoint inhibitor efficacy for non‐small cell lung cancer},
  journal = {International Journal of Cancer},
  year = {2026},
  doi = {10.1002/ijc.70170}
}
Kostenlos starten →